

# ZKB Tracker Certificate on global eHealth equity basket

18.10.2021 - 18.10.2023 | Swiss Security Code 110 588 360

## Summary

This Summary is to be understood as an introduction to the present indicative Final Terms. Any investment decision in relation to the products must be based on the information contained in the base prospectus and in these indicative Final Terms in their entirety and not on the Summary. In particular, each investor should consider the risk factors contained in these indicative Final Terms and in the base prospectus. The Issuer can only be held liable for the content of this Summary if the Summary is misleading, incorrect or contradictory when read together with the other parts of the indicative Final Terms and the base prospectus.

Information on the securities
<b>Type of product:</b> ZKB Tracker Certificate <b>SSPA Category:</b> Tracker Certificate (1300, acc. to the Swiss Derivative Map) <b>ISIN:</b> CH1105883602 <b>Symbol:</b> GEHABZ <b>Issuer:</b> Zürcher Kantonalbank <b>Underlying:</b> global eHealth equity basket <b>Initial Fixing Date:</b> 11 October 2021 <b>Settlement Date:</b> 18 October 2021 <b>Final Fixing Date:</b> 11 October 2023 <b>Redemption Date:</b> 18 October 2023 <b>Type of settlement:</b> cash
Information concerning the offer and admission to trading
<b>Place of the offer:</b> Switzerland <b>Subscription period:</b> 8 October 2021, 16:00h CET** <b>Notional Amount/Denomination/Trading Units:</b> CHF 25'000'000.00**/CHF 100.00**/1 structured product or multiples thereof <b>Issue price:</b> CHF 100.00** <b>Information on listing:</b> Application to list on the SIX Swiss Exchange will be filed, planned first trading day will be 18 October 2021

## Indicative Final Terms

\*\* The information contained is merely indicative. The Issuer/Calculation Agent will fix the legally binding parameters on the Initial Fixing Date. The subscriber/investor takes notice of the fact, that the final and legally binding conditions of the present structured product will not be fixed until Initial Fixing Date. Furthermore, in subscribing to the present structured product, the Investor agrees to the final conditions.

### 1. Product Description

#### Product Category/Name

Participation Product/Tracker Certificate (1300, according to the Swiss Derivative Map provided by the Swiss Structured Products Association)

#### Regulatory Notification

**This product does not constitute a collective investment scheme within the meaning of the Swiss Federal Act on Collective Investment Schemes (CISA) and it is not subject to authorisation or supervision by FINMA. The issuer risk is borne by investors.**

#### Investment Profile

...

#### Issuer

Zürcher Kantonalbank, Zurich

#### Lead Manager, Paying Agent, Exercise Agent and Calculation Agent

Zürcher Kantonalbank, Zurich

#### Rating of the Issuer

Standard & Poor's AAA, Moody's Aaa, Fitch AAA

<b>Symbol/ Swiss Security Code/ISIN</b>	<b>GEHABZ/ 110 588 360/CH1105883602</b>					
<b>Notional Amount/Denomination/ Trading Units</b>	CHF 25'000'000.00**/CHF 100.00**/1 structured product or multiples thereof					
<b>Number of structured products</b>	Up to 250'000**, with the right to increase					
<b>Issue Price</b>	<b>CHF 100.00/101.52%**</b> of Basket Value on the Initial Fixing Date					
<b>Currency</b>	CHF					
<b>Underlying</b>	<b>Component</b>	<b>ISIN / Bloomberg</b>	<b>Related Exchange</b>	<b>*Currency / Initial Fixing Value**</b>	<b>Weight in %**</b>	<b>No. of Shares**</b>
	Alibaba Health Information Technology Ltd	BMG0171K1018 / 241 HK	Hong Kong Stock Exchange	HKD 0.00001	4.35	0.00001
	Anthem Inc	US0367521038 / ANTM UN	New York Stock Exchange	USD 0.00001	4.35	0.00001
	Centene Corp	US15135B1017 / CNC UN	New York Stock Exchange	USD 0.00001	4.35	0.00001
	Cerner Corp	US1567821046 / CERN UW	NASDAQ	USD 0.00001	4.35	0.00001
	Cigna Corp	US1255231003 / CI UN	New York Stock Exchange	USD 0.00001	4.35	0.00001
	CompuGroup Medical SE & Co. KGaA	DE000A288904 / COP GY	Xetra	EUR 0.00001	4.35	0.00001
	EMIS Group PLC	GB00B61D1Y04 / EMIS LN	London Stock Exchange	GBP 0.00001	4.35	0.00001
	Fulgent Genetics Inc	US3596641098 / FLGT UQ	NASDAQ GM	USD 0.00001	4.35	0.00001
	Genpact Ltd	BMG3922B1072 / G UN	New York Stock Exchange	USD 0.00001	4.35	0.00001
	Healthcare Limited	AU000000SHL7 / SHL AT	Australian Securities Exchange	AUD 0.00001	4.35	0.00001
	Humana Inc	US4448591028 / HUM UN	New York Stock Exchange	USD 0.00001	4.35	0.00001
	IQVIA Holdings Inc	US46266C1053 / IQV UN	New York Stock Exchange	USD 0.00001	4.35	0.00001
	JD Health International Inc	KYG5074A1004 / 6618 HK	Hong Kong Stock Exchange	HKD 0.00001	4.35	0.00001
	Medtronic PLC	IE00BTN1Y115 / MDT UN	New York Stock Exchange	USD 0.00001	4.35	0.00001
	NextGen Healthcare Inc	US65343C1027 / NXGN UW	NASDAQ GS	USD 0.00001	4.35	0.00001
	Qiagen NV	NL0012169213 / QIA GY	Xetra	EUR 0.00001	4.35	0.00001
	Shop Apotheke Europe NV	NL0012044747 / SAE GY	Xetra	EUR 0.00001	4.35	0.00001
	Siemens Healthineers AG	DE000SHL1006 / SHL GY	Xetra	EUR 0.00001	4.35	0.00001
	Tabula Rasa HealthCare Inc	US8733791011 / TRHC UQ	NASDAQ GM	USD 0.00001	4.35	0.00001
	Teladoc Health Inc	US87918A1051 / TDOC UN	New York Stock Exchange	USD 0.00001	4.35	0.00001
	Thermo Fisher Scientific Inc	US8835561023 / TMO UN	New York Stock Exchange	USD 0.00001	4.35	0.00001
	Unitedhealth Group Inc	US91324P1021 / UNH UN	New York Stock Exchange	USD 0.00001	4.35	0.00001
	Zur Rose Group AG	CH0042615283 / ROSE SE	SIX Swiss Exchange	CHF 0.00001	4.35	0.00001

\* Local taxes, transactions fees and foreign commissions are, if applicable, included in the Initial Fixing Value of each component and are thus borne by the holders of the structured product. This applies particularly, though not exclusively, when exercising rights associated with the structured product and/or a Rebalancing.

**Basket Value** CHF 98.50\*\* on Initial Fixing Date

<b>Ratio</b>	1 ZKB Tracker Certificate represents 1 Underlying
<b>Dividend Payments</b>	No dividends will be paid out. The dividend as a whole will be reinvested into the structured product in the form of a net dividend.
<b>Subscription Period</b>	Subscriptions for these structured products may be made <b>until 8 October 2021, 16:00 CET**</b> . The Issuer shall have the right to reduce the number of structured products issued or to withdraw them from the issue for any reason. Furthermore, the Issuer shall have the right to close the offer prematurely or to postpone the Subscription Period.
<b>Initial Fixing Date</b>	11 October 2021
<b>Settlement Date</b>	18 October 2021
<b>Right to return of the Investor</b>	In addition to the possibility of selling the structured products in the secondary market, the investor has the right to return the product annually per 15th day of December (fixing date; modified following) to the Issuer, for the first time on 15 December 2021. On the fixing date, the redemption amount is determined, which is governed by the information under the section Redemption Method. The Issuer has the right to expand the time period for the Final Fixing if required by current market conditions e.g. liquidity. The declaration of intent to exercise the Right to return must be received no later than 5 banking days before the respective fixing date (exercise date) by Zürcher Kantonalbank and must be sent to the following address: by letter post to Zürcher Kantonalbank, Sales structured products, IHHV, P.O. Box, 8010 Zürich or by email to <a href="mailto:derivate@zkb.ch">derivate@zkb.ch</a> . The repayment will be executed with a value date of 5 bank working days after the fixing date (Redemption Date). Should the structured products of the Investor be deposited in a custodian bank, the Investor needs additionally and in due time advise/inform his custodian bank according the notice of redemption.
<b>Last Trading Date</b>	10 October 2023
<b>Final Fixing Date</b>	11 October 2023 The Issuer has the right to expand the time period for the Final Fixing if required by current market conditions e.g. liquidity.
<b>Redemption Date</b>	18 October 2023
<b>Initial Fixing Level</b>	11 October 2021, 15:30 CET, Net price of the Components of the Underlying on a best effort basis. Local taxes, transactions fees and foreign commissions are included in the Initial Fixing Value of each component if applicable.
<b>Final Fixing Level</b>	Closing prices of the components of the Underlying on Related Exchanges, on 11 October 2023 Local taxes, transactions fees and foreign commissions are included in the Final Fixing Value of each component if applicable.
<b>Redemption Method</b>	On Redemption Date, investors receive in cash for every certificate 100% of the Underlying as defined on the relevant fixing date/Final Fixing Date and according to the following formula: $Ratio * ( \sum_{i=1}^N S_{i,T} * W_{i,T} * FX_{i,T} ) - Fees$ <p>where</p> <p>Ratio = 1**</p> <p><math>S_{i,T}</math> = Value of the Component i of the Underlying on relevant fixing date/Final Fixing Date</p> <p><math>W_{i,T}</math> = Weighting of the Component i of the Underlying (number of Shares) on relevant fixing date/Final Fixing Date</p> <p>Fees = Annual Fee</p> <p><math>FX_{i,T}</math> = Exchange rate of the Component i of the Underlying (to CHF) on relevant fixing date/Final Fixing Date</p> <p>T = Relevant fixing date/Final Fixing Date</p> <p>If capital events that were unknown at the time of issue take place during the life of the ZKB Tracker Certificate, they shall be taken into account by adjusting the weighting of the affected Component of the Underlying accordingly.</p>
<b>Listing/Secondary market</b>	Application to list on the SIX Swiss Exchange will be filed, planned first trading day will be 18 October 2021.

<b>Annual Fee</b>	0.25% p.a. The Annual Fee will be charged based on the value of the structured product and is pro rata temporis included in the trading price.
<b>Clearing House</b>	SIX SIS AG/Euroclear/Clearstream
<b>Distribution fees</b>	Distribution fees in the form of a discount on the Issue price, reimbursement of a part of the Issue price or other one-off and/or periodic charges may have been paid to one or several distribution partners of this structured product. Distribution fees paid to distribution partners may amount up to 0.5000% p.a.
<b>Sales: 044 293 66 65</b>	SIX Telekurs: .zkb Internet: www.zkb.ch/finanzinformationen
	Reuters: ZKBSTRUCT Bloomberg: ZKBY <go>
<b>Key Elements of the product</b>	In terms of value, buying a ZKB Tracker Certificate is equivalent to buying the Underlying less any Fees. A single, low-cost transaction gives investors the opportunity to participate fully in the performance of the Underlying. Dividend Payments of underlying components in the basket are paid out to the investor by means of Dividend reinvestment in the Underlying. Redemption is based on the weighted value of Underlying components on the Final Fixing Date.
<b>Taxes</b>	For private investors with Swiss tax domicile, the reinvested dividends are subject to Swiss income tax at maturity. The product is not subject to Swiss withholding tax. The Federal securities transfer stamp tax is not levied on secondary market transactions. This product may be subject to additional withholding taxes or duties, such as related to FATCA, Sect. 871(m) U.S. Tax Code or foreign financial transaction taxes. Any payments due under this product are net of such taxes or duties. The information above is a summary only of the Issuer's understanding of current law and practice in Switzerland relating to the taxation of structured products. The relevant tax law and practice may change. The Issuer does not assume any liability in connection with the above information. The tax information only provides a general overview and can not substitute the personal tax advice to the investor.
<b>Documentation</b>	This document is a non-binding English translation of the indicative Final Terms (vorläufige Endgültige Bedingungen) published in German and constituting the indicative Final Terms in accordance with article 45 of the Federal Act on Financial Services (FinSA). The English language translation is provided for convenience only. The binding German version of these indicative Final Terms supplements the base prospectus approved by the SIX Exchange Regulation Ltd and published in German by the Issuer on 16 November 2020. These indicative Final Terms constitute a simplified prospectus pursuant to article 5 para. 2 CISA in the version dated 1 March 2013. Together with the base prospectus (and together with any supplements) these indicative Final Terms form the product documentation for this issue. If this product was the first time issued under the base prospectus of 16 November 2020, these indicative Final Terms must be read in conjunction with the General Terms of the Securities (Allgemeine Bedingungen der Derivate), the Additional Terms and the Information on the Underlyings in the base prospectus of 16 November 2020. If this product has been issued prior to the date of the base prospectus of 16 November 2020, these indicative Final Terms shall be read in conjunction with the base prospectus of 16 November 2020 and together with the Existing Terms of the products from the version of the Issuance Programme or base prospectus in force at the time of issuance that has been incorporated by reference in this base prospectus. The base prospectus of the Issuer dated 16 November 2020 will cease to be valid on 16 November 2021. From and including this date, these indicative Final Terms must be read together with the latest valid version of the base prospectus of the Issuer (including the information incorporated by reference into the latest valid version of the base prospectus from the base prospectus under which the products the first time were issued), which follows the base prospectus of 16 November 2020. Except as otherwise defined in these indicative Final Terms, the terms used in these indicative Final Terms have the meaning given to them in the base prospectus. In case of discrepancies between information or the provisions in these indicative Final Terms and those in the base prospectus, the information and provisions in these indicative Final Terms shall prevail. In the event of a listing of the products, the product documentation will be adapted, if and to the extent necessary, in accordance with the requirements of the relevant exchange. The present products will be issued in the form of uncertificated securities (Wertrechte) and registered as book-entry securities (Bucheffekten) with SIX SIS AG. Investors have no right to require the issuance of any certificates or any proof of evidence for the products. <b>These indicative Final Terms and the base prospectus can be ordered free of charge at Zürcher Kantonalbank, Bahnhofstrasse 9, 8001 Zurich, dept. VRIE or by e-mail at <a href="mailto:documentation@zkb.ch">documentation@zkb.ch</a>. They are also available on <a href="https://www.zkb.ch/finanzinformationen">https://www.zkb.ch/finanzinformationen</a>.</b>

## Information on the Underlying

Information on the performance of the Underlying/a component of the Underlying is publicly available on [www.bloomberg.com](http://www.bloomberg.com). Current annual reports are published on the website of the respective business entity. The transfer of the Underlying/a component of the Underlying is conducted in accordance with their respective statutes.

## Notices

Any notice by the Issuer in connection with these structured products, in particular any notice in connection with modifications of the terms and conditions will be validly published on the website <https://www.zkb.ch/finanzinformationen> under the relevant structured product. The Swiss security code search button will lead you directly to the relevant structured product. The notices will be published in accordance with the rules issued by SIX Swiss Exchange for IBL (Internet Based Listing) on the website

<https://www.six-exchange-regulation.com/en/home/publications/official-notices.html>

## Governing Law/Jurisdiction

Swiss Law/Zurich

## 2. Profit and Loss Expectations after Year 1

### Profit and Loss Expectations after Year 1

ZKB Tracker Certificate\*\*

Basket		Redemption	
Value	Percent	ZKB Tracker Certificate	Performance %
CHF 39.40	-60.00%	CHF 39.3	-60.7%
CHF 59.10	-40.00%	CHF 58.95	-41.05%
CHF 78.80	-20.00%	CHF 78.6	-21.4%
CHF 100.00	+1.52%	CHF 99.75	-0.25%
CHF 118.20	+20.00%	CHF 117.9	17.9%
CHF 137.90	+40.00%	CHF 137.56	37.56%
CHF 157.60	+60.00%	CHF 157.21	57.21%

Source: Zürcher Kantonalbank

The performance of the ZKB Tracker Certificate is analog to the performance of the Underlying less any Fees. Therefore, the investor may suffer a partial or total loss.

The figures in the table above are valid after Year 1 only and cannot be considered as a price indication for the present structured product during its lifetime. The price quoted in the secondary market can differ substantially from the table above. For presentation purposes it is assumed, that the currency of the Underlying remains constant during the lifetime of the present structured product.

## 3. Material Risks for Investors

### Credit Risk Relating to Issuer

Obligations under these structured products constitute direct, unconditional and unsecured obligations of the Issuer and rank pari passu with other direct, unconditional and unsecured obligations of the Issuer. The value of the structured product does not only depend on the performance of the Underlying and other developments in the financial markets, but also on the solvency of the Issuer, which may change during the term of this structured product.

### Specific Product Risks

Structured products are complex financial instruments, which entail considerable risks and, accordingly, are only suitable for investors who have the requisite knowledge and experience and understand thoroughly the risks connected with an investment in these structured products and are capable of bearing the economic risks.

ZKB Tracker Certificate is an investment product whose price fluctuates to the same degree as the Underlying less any Fees. Depending on price trends, the price of a ZKB Tracker Certificate could fall below the Issue Price. The risk profile of the ZKB Tracker Certificate corresponds to that of the Underlying. The ZKB Tracker Certificate is denominated in CHF. The investor bears all the risks in connection with a possible exchange rate risk between the product currency, the currency of the components of the Underlying, and his reference currency.

Investments with regard to Emerging Markets are exposed to several risk factors especially political or economic risks. The political system, the continuity and the political culture of emerging markets might be totally different compared to developed countries and might therefore cause a negative influence on the Underlying and/or the currencies. The relevant Underlyings and currencies are generally not as liquid as those of developed countries. Purchase and sales might cause market fluctuations. Especially in emerging markets currency transfer restrictions and/or a connectivity to a reference currency are more likely.

#### 4. Additional Terms

##### **Modifications**

If an extraordinary event as described in the base prospectus occurs in relation to the Underlying/a component of the Underlying or if any other extraordinary event occurs, which makes it impossible or particularly cumbersome for the Issuer, to fulfill its obligations under the products or to calculate the value of the products, the Issuer shall at its own discretion take all the necessary actions and, if necessary may modify the terms and conditions of these products at its own discretion in such way, that the economic value of the products after occurrence of the extraordinary event corresponds, to the extent possible, to the economic value of the products prior to the occurrence of the extraordinary event. Specific modification rules for certain types of Underlyings stated in the base prospectus shall prevail. If the Issuer determines, for whatever reason, that an adequate modification is not possible, the Issuer has the right to redeem the products early.

##### **Market Disruptions**

Compare specific provisions in the base prospectus.

##### **Substitution of Underlying**

During the term of the structured product, changes in or substitution of the Underlying by the Calculation Agent can occur. In this case, it cannot be ruled out that such changes or substitutions will negatively affect the value of the structured product. Likewise, it cannot be ruled out that in the case of a structured product based on an index that changes in the composition of the index as a result of change or substitutions in respect of individual index components, for example, as a result of the withdrawal or addition of individual securities, may negatively influence the price of the index and accordingly the value of the structured product.

##### **Prudential Supervision**

As a bank within the meaning of the Swiss Federal Act on Banks and Savings Banks (BankG; SR 952.0) and a securities firm within the meaning of the Swiss Federal Act on Financial Institutions (FinlAG; SR 954.1), Zürcher Kantonalbank is subject to the prudential supervision of FINMA, Laupenstrasse 27, CH-3003 Bern, <https://www.finma.ch>.

##### **Recording of Telephone Conversations**

Investors are reminded that telephone conversations with trading or sales units of Zürcher Kantonalbank are recorded. Investors, engaging in telephone conversations with these units provide their tacit consent to the recording of their conversations.

##### **Further Information**

This document constitutes neither an offer nor a recommendation or invitation to purchase financial instruments and can't replace the individual investor's own judgement. The information contained in this document does not constitute investment advice but is intended solely as a product description. An investment decision should in any case be made on the basis of these Final Terms and the base prospectus. Particularly, before entering into a transaction, the investor should, if necessary with the assistance of an advisor, examine the conditions for investment in the product in consideration of his personal situation with regard to legal, regulatory, tax and other consequences. Only an investor who is aware of the risks of the transaction and has the financial capacity to bear any losses should enter into such transactions.

##### **Material Changes**

Since the end of the last financial year or the date of the interim financial statements, there have been no material changes in the assets, financial or revenue position of the Issuer.

##### **Responsibility for the indicative Final Terms**

Zürcher Kantonalbank, Zurich, assumes responsibility for the content of these indicative Final Terms and hereby declares that, to its knowledge, the information contained in these indicative Final Terms is correct and no material circumstances have been omitted.

Zurich, 27 September 2021